BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jun 21, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Ii-Key/HER2/neu cancer vaccine: Additional Phase II data

Additional data from a Phase II trial in 150 disease-free breast cancer patients with a high risk of relapse showed that 6 monthly inoculations of AE37 adjuvanted with granulocyte macrophage-colony stimulating factor (GM-CSF) resulted in a non-significantly lower relapse rate vs. GM-CSF alone at...

Read the full 200 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >